We are live on ! Find out more
GERM

Amplify Treatments, Testing and Advancements ETF
GERM

Delisted

GERM was delisted on the 5th of September, 2024.

Back to rankings

16 hedge funds and large institutions have $1.72M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 17 → 16 (-1)

50% less capital invested

Capital invested by funds: $3.43M → $1.72M (-$1.71M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$180K
2
Morgan Stanley
Morgan Stanley
New York
+$20

Top Sellers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
-$798K
2
Goldman Sachs
Goldman Sachs
New York
-$496K
3
Citadel Advisors
Citadel Advisors
Florida
-$189K
4
UBS Group
UBS Group
Switzerland
-$67.2K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$25.9K

GERM Hedge Fund Activity: Q3 2023 in Review

16 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q3 2023, worth a combined $1.72M — down 50% from $3.43M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of GERM and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 1 added.

The largest buyer was Susquehanna International Group, adding an estimated $180K. The largest seller was LPL Financial, exiting entirely with an estimated $798K sold.

  • 16 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q3 2023, down from 17 in Q2 2023.
  • Funds reported $1.72M of Amplify Treatments, Testing and Advancements ETF stock for Q3 2023, down 50% quarter-over-quarter.
  • 1 fund opened new Amplify Treatments, Testing and Advancements ETF positions in Q3 2023 and 2 closed out, a net change of -1 holder.
  • The largest Amplify Treatments, Testing and Advancements ETF buyer in Q3 2023 was Susquehanna International Group, an estimated $180K added.
  • The largest Amplify Treatments, Testing and Advancements ETF seller in Q3 2023 was LPL Financial, an estimated $798K sold.

Based on aggregated 13F filings for Q3 2023.